Spencer Phillips Hey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Spencer Phillips Hey has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Charles Weijer
Department of Medicine, Western University, London, Canada
7 shared publications - Monica Taljaard
Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
5 shared publications - Merrick Zwarenstein
Departments of Family Medicine and of Epidemiology/Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada; ICES Western, London, Ontario, Canada
4 shared publications - Stuart Gordon Nicholls
The Ottawa Hospital Research Institute
4 shared publications - Cory E. Goldstein
Methodological and Implementation Research Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
3 shared publications - Dean Fergusson
Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by Springer Nature in Implementation Science Communications
- Vol. 7 (1)
Large language models for deductive qualitative content analysis in dementia-focused embedded pragmatic clinical trials: A comparative methodological study
Thematic coding helps researchers characterize intervention implementation in embedded pragmatic clinical trials (ePCTs), particularly interventions for ol
- 6 May 2026
- Published by Springer Nature in Implementation Science Communications
- Vol. 7 (1)
Open AccessLarge language models for deductive qualitative content analysis in dementia-focused embedded pragmatic clinical trials: A comparative methodological study
Thematic coding helps researchers characterize intervention implementation in embedded pragmatic clinical trials (ePCTs), particularly interventions for ol
- Open Access
- 20 December 2024
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 40 (16) , 3916-3919
Flying Blind: How Thorough are IRBs when Assessing Scientific Value?
Background: Institutional Review Boards (IRBs) in the United States play a crucial role in ensuring the ethical conduct of clinical trials, including assessing the scientific merit of studies to justify the risks to participants. However, prior research suggests that many IRBs do not systematically evaluate scientific merit, raising concerns about the approval of low-quality trials. Objective: To investigate whether IRBs provide adequate guidance on assessing scientific merit in their Standard Operating Procedures (SOPs) and other relevant materials. Design: A systematic pilot investigation of IRB SOPs and related guidance documents from a sample of U.S.-based non-profit institutions. Participants: IRB materials from 35 U.S.-based non-profit institutions selected from the FDA’s Bioresearch Monitoring Information System database, representing 39.9% of submissions between 2018 and 2021. Additionally, materials from one U.S.-based for-profit IRB were included. Interventions: Not applicable. Main Measures: The presence of guidance on 15 dimensions of scientific merit, clustered into four PICO (Population, Intervention, Comparator, Outcome) categories, was assessed by reviewing IRB SOPs and related documents. Evidence of guidance was determined by mention of keywords related to each dimension. Key Results: Most IRB materials mentioned basic study elements such as study design (99%), subject recruitment (90%), and intervention justification (97%). However, critical aspects related to study quality, such as bias reduction (53%) and outcome measurement tools (57%), were less frequently mentioned. The least represented dimension was confounder control (10%). Conclusions: IRB guidance materials vary in their coverage of scientific merit dimensions, with significant gaps in areas critical for assessing study quality. Strengthening guidance materials by including comprehensive instructions for all 15 dimensions could improve IRB assessments of scientific merit, thereby enhancing the ethical oversight of clinical trials.
- 20 December 2024
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 40 (16) , 3916-3919
Open AccessFlying Blind: How Thorough are IRBs when Assessing Scientific Value?
Background: Institutional Review Boards (IRBs) in the United States play a crucial role in ensuring the ethical conduct of clinical trials, including assessing the scientific merit of studies to justify the risks to participants. However, prior research suggests that many IRBs do not systematically evaluate scientific merit, raising concerns about the approval of low-quality trials. Objective: To investigate whether IRBs provide adequate guidance on assessing scientific merit in their Standard Operating Procedures (SOPs) and other relevant materials. Design: A systematic pilot investigation of IRB SOPs and related guidance documents from a sample of U.S.-based non-profit institutions. Participants: IRB materials from 35 U.S.-based non-profit institutions selected from the FDA’s Bioresearch Monitoring Information System database, representing 39.9% of submissions between 2018 and 2021. Additionally, materials from one U.S.-based for-profit IRB were included. Interventions: Not applicable. Main Measures: The presence of guidance on 15 dimensions of scientific merit, clustered into four PICO (Population, Intervention, Comparator, Outcome) categories, was assessed by reviewing IRB SOPs and related documents. Evidence of guidance was determined by mention of keywords related to each dimension. Key Results: Most IRB materials mentioned basic study elements such as study design (99%), subject recruitment (90%), and intervention justification (97%). However, critical aspects related to study quality, such as bias reduction (53%) and outcome measurement tools (57%), were less frequently mentioned. The least represented dimension was confounder control (10%). Conclusions: IRB guidance materials vary in their coverage of scientific merit dimensions, with significant gaps in areas critical for assessing study quality. Strengthening guidance materials by including comprehensive instructions for all 15 dimensions could improve IRB assessments of scientific merit, thereby enhancing the ethical oversight of clinical trials.
- Open Access
- 6 August 2023
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 57 (6) , 1269-1278
Digital Health Technologies in Clinical Trials: An Ontology-Driven Analysis to Inform Digital Sustainability Policies
Background: Digital health technologies (DHTs) can facilitate the execution of de-centralized trials that can offer opportunities to reduce the burden on participants, collect outcome data in a real-world setting, and potentially make trial populations more diverse and inclusive. However, DHTs can also be a significant source of electronic waste (e-waste). In recognition of the potential health and environmental impact from DHT use in trials, private and public institutions have recently launched initiatives to help measure and manage this e-waste. But in order to develop sound e-waste management policies, it will be necessary to first estimate the current volume of e-waste that results from the use of DHTs in trials. Materials and Methods: A Web Ontology Language (OWL)-compliant ontology of DHTs was created using a list of 500 DHT device names derived from a mixture of public and private sources. The U.S. clinical trials registry, ClinicalTrials.gov, was then queried to identify and classify trials using any of the devices in the ontology. The ClinicalTrials.gov records from this search were then analyzed to characterize the volume and properties of trials using DHTs, as well as estimating the total volume of individual DHT units that have been provisioned (or are planned to be provisioned) for clinical research. Results: Our ontology-driven search identified 2326 unique clinical trials with a reported “actual” enrollment of 200,947 participants and a “planned” enrollment of an additional 4,094,748 participants. The most-used class of DHTs in our ontology was “wearables,” (1852 trials), largely driven by the use of smart watches and other wrist-worn sensors (estimated to involve 149,391 provisioned devices). The most-used subtype of DHTs in trials was “subcutaneous” devices (367 trials), driven by the prevalent use and testing of glucose monitors (estimated to involve 17,666 provisioned devices). Conclusion: Thousands of trials, involving hundreds of thousands of devices, have already been completed, and many more trials (potentially involving millions more devices) are planned. Despite the great opportunities that are afforded by DHTs to the clinical trial enterprise, if the industry lacks the ability to track DHT use with sufficient resolution, the result is likely to be a great deal of e-waste. A new ontology of DHTs, combined with rigorous data science methods like those described in this paper, can be used to provide better information across the industry, and in turn, help create a more sustainable and equitable clinical trials enterprise.
- 6 August 2023
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 57 (6) , 1269-1278
Open AccessDigital Health Technologies in Clinical Trials: An Ontology-Driven Analysis to Inform Digital Sustainability Policies
Background: Digital health technologies (DHTs) can facilitate the execution of de-centralized trials that can offer opportunities to reduce the burden on participants, collect outcome data in a real-world setting, and potentially make trial populations more diverse and inclusive. However, DHTs can also be a significant source of electronic waste (e-waste). In recognition of the potential health and environmental impact from DHT use in trials, private and public institutions have recently launched initiatives to help measure and manage this e-waste. But in order to develop sound e-waste management policies, it will be necessary to first estimate the current volume of e-waste that results from the use of DHTs in trials. Materials and Methods: A Web Ontology Language (OWL)-compliant ontology of DHTs was created using a list of 500 DHT device names derived from a mixture of public and private sources. The U.S. clinical trials registry, ClinicalTrials.gov, was then queried to identify and classify trials using any of the devices in the ontology. The ClinicalTrials.gov records from this search were then analyzed to characterize the volume and properties of trials using DHTs, as well as estimating the total volume of individual DHT units that have been provisioned (or are planned to be provisioned) for clinical research. Results: Our ontology-driven search identified 2326 unique clinical trials with a reported “actual” enrollment of 200,947 participants and a “planned” enrollment of an additional 4,094,748 participants. The most-used class of DHTs in our ontology was “wearables,” (1852 trials), largely driven by the use of smart watches and other wrist-worn sensors (estimated to involve 149,391 provisioned devices). The most-used subtype of DHTs in trials was “subcutaneous” devices (367 trials), driven by the prevalent use and testing of glucose monitors (estimated to involve 17,666 provisioned devices). Conclusion: Thousands of trials, involving hundreds of thousands of devices, have already been completed, and many more trials (potentially involving millions more devices) are planned. Despite the great opportunities that are afforded by DHTs to the clinical trial enterprise, if the industry lacks the ability to track DHT use with sufficient resolution, the result is likely to be a great deal of e-waste. A new ontology of DHTs, combined with rigorous data science methods like those described in this paper, can be used to provide better information across the industry, and in turn, help create a more sustainable and equitable clinical trials enterprise.
- 18 August 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 151, 113-121
An analysis of published trials found that current use of pragmatic trial labels is uninformative
- 18 August 2022
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 151, 113-121
An analysis of published trials found that current use of pragmatic trial labels is uninformative
- 22 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (540)
The evidence landscape in precision medicine
Evidence landscapes can help to coordinate research and address challenges in implementing precision medicine.
- 22 April 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (540)
The evidence landscape in precision medicine
Evidence landscapes can help to coordinate research and address challenges in implementing precision medicine.
- 1 January 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (1) , 131-138
US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals
Importance Regulatory and scientific guidelines stipulate that indirect, surrogate measures of patient benefit, such as a change in microbial culture status, should be used as primary end points only in pivotal trials of chronic conditions that are serious or life threatening and when the experimental therapy is expected to offer substantial benefit compared with available therapy. However, many recent US Food and Drug Administration (FDA) anti-infective drug approvals for acute and/or non–life-threatening diseases have been based on pivotal trials using surrogate measures as primary end points rather than clinical outcomes, such as symptom resolution or survival. Objectives To review FDA recommendations for primary end points in pivotal trials of new anti-infective drugs and assess the concordance of those recommendations with the regulatory and scientific conditions for the appropriate use of surrogate measures as primary trial outcomes. Evidence Review All guidance documents for antimicrobial drug development hosted on the FDA website were searched in November 2017; the search was updated in June 2018. For each document, 2 reviewers independently extracted data on the recommended primary end points for a pivotal or phase 3 trial. Findings Twenty-two FDA guidance documents met the inclusion criteria, which included recommendations for primary end points in pivotal clinical trials in 27 infectious disease indications. Twenty-one of 27 indications recommended surrogate outcomes as either the sole primary end point or as components of composite end points. None of the recommendations for the use of surrogate measures matched the regulatory and scientific conditions favoring indirect outcomes in place of clinical outcomes. Conclusions and Relevance The FDA guidance documents for developing new anti-infective agents frequently recommend indirect measures of patient benefit, rather than direct measures of patient benefit, as sole primary end points or components of primary end points. Existing guidance documents should be updated and revised to recommend appropriate clinical outcomes consistent with general scientific and regulatory parameters.
- 1 January 2020
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 180 (1) , 131-138
US Food and Drug Administration Recommendations on the Use of Surrogate Measures as End Points in New Anti-infective Drug Approvals
Importance Regulatory and scientific guidelines stipulate that indirect, surrogate measures of patient benefit, such as a change in microbial culture status, should be used as primary end points only in pivotal trials of chronic conditions that are serious or life threatening and when the experimental therapy is expected to offer substantial benefit compared with available therapy. However, many recent US Food and Drug Administration (FDA) anti-infective drug approvals for acute and/or non–life-threatening diseases have been based on pivotal trials using surrogate measures as primary end points rather than clinical outcomes, such as symptom resolution or survival. Objectives To review FDA recommendations for primary end points in pivotal trials of new anti-infective drugs and assess the concordance of those recommendations with the regulatory and scientific conditions for the appropriate use of surrogate measures as primary trial outcomes. Evidence Review All guidance documents for antimicrobial drug development hosted on the FDA website were searched in November 2017; the search was updated in June 2018. For each document, 2 reviewers independently extracted data on the recommended primary end points for a pivotal or phase 3 trial. Findings Twenty-two FDA guidance documents met the inclusion criteria, which included recommendations for primary end points in pivotal clinical trials in 27 infectious disease indications. Twenty-one of 27 indications recommended surrogate outcomes as either the sole primary end point or as components of composite end points. None of the recommendations for the use of surrogate measures matched the regulatory and scientific conditions favoring indirect outcomes in place of clinical outcomes. Conclusions and Relevance The FDA guidance documents for developing new anti-infective agents frequently recommend indirect measures of patient benefit, rather than direct measures of patient benefit, as sole primary end points or components of primary end points. Existing guidance documents should be updated and revised to recommend appropriate clinical outcomes consistent with general scientific and regulatory parameters.
- Open Access
- 23 December 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-16
The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders
Background: There is a concern that the apparent effectiveness of interventions tested in clinical trials may not be an accurate reflection of their actual effectiveness in usual practice. Pragmatic randomized controlled trials (RCTs) are designed with the intent of addressing this discrepancy. While pragmatic RCTs may increase the relevance of research findings to practice they may also raise new ethical concerns (even while reducing others). To explore this question, we interviewed key stakeholders with the aim of identifying potential ethical challenges in the design and conduct of pragmatic RCTs with a view to developing future guidance on these issues.Methods: Interviews were conducted with clinical investigators, methodologists, patient partners, ethicists, and other knowledge users (e.g., regulators). Interviews covered experiences with pragmatic RCTs, ethical issues relevant to pragmatic RCTs, and perspectives on the appropriate oversight of pragmatic RCTs. Interviews were coded inductively by two coders. Interim and final analyses were presented to the broader team for comment and discussion before the analytic framework was finalized.Results: We conducted 45 interviews between April and September 2018. Interviewees represented a range of disciplines and jurisdictions as well as varying content expertise. Issues of importance in pragmatic RCTs were (1) identification of relevant risks from trial participation and determination of what constitutes minimal risk; (2) determining when alterations to traditional informed consent approaches are appropriate; (3) the distinction between research, quality improvement, and practice; (4) the potential for broader populations to be affected by the trial and what protections they might be owed; (5) the broader range of trial stakeholders in pragmatic RCTs, and determining their roles and responsibilities; and (6) determining what constitutes “usual care” and implications for trial reporting.Conclusions: Our findings suggest both the need to discuss familiar ethical topics in new ways and that there are new ethical issues in pragmatic RCTs that need greater attention. Addressing the highlighted issues and developing guidance will require multidisciplinary input, including patient and community members, within a broader and more comprehensive analysis that extends beyond consent and attends to the identified considerations relating to risk and stakeholder roles and responsibilities.
- 23 December 2019
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-16
Open AccessThe ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders
Background: There is a concern that the apparent effectiveness of interventions tested in clinical trials may not be an accurate reflection of their actual effectiveness in usual practice. Pragmatic randomized controlled trials (RCTs) are designed with the intent of addressing this discrepancy. While pragmatic RCTs may increase the relevance of research findings to practice they may also raise new ethical concerns (even while reducing others). To explore this question, we interviewed key stakeholders with the aim of identifying potential ethical challenges in the design and conduct of pragmatic RCTs with a view to developing future guidance on these issues.Methods: Interviews were conducted with clinical investigators, methodologists, patient partners, ethicists, and other knowledge users (e.g., regulators). Interviews covered experiences with pragmatic RCTs, ethical issues relevant to pragmatic RCTs, and perspectives on the appropriate oversight of pragmatic RCTs. Interviews were coded inductively by two coders. Interim and final analyses were presented to the broader team for comment and discussion before the analytic framework was finalized.Results: We conducted 45 interviews between April and September 2018. Interviewees represented a range of disciplines and jurisdictions as well as varying content expertise. Issues of importance in pragmatic RCTs were (1) identification of relevant risks from trial participation and determination of what constitutes minimal risk; (2) determining when alterations to traditional informed consent approaches are appropriate; (3) the distinction between research, quality improvement, and practice; (4) the potential for broader populations to be affected by the trial and what protections they might be owed; (5) the broader range of trial stakeholders in pragmatic RCTs, and determining their roles and responsibilities; and (6) determining what constitutes “usual care” and implications for trial reporting.Conclusions: Our findings suggest both the need to discuss familiar ethical topics in new ways and that there are new ethical issues in pragmatic RCTs that need greater attention. Addressing the highlighted issues and developing guidance will require multidisciplinary input, including patient and community members, within a broader and more comprehensive analysis that extends beyond consent and attends to the identified considerations relating to risk and stakeholder roles and responsibilities.
- 19 December 2019
- Published by Springer Nature in Journal of Bioethical Inquiry
- Vol. 17 (1) , 29-35
Why High Drug Pricing Is A Problem for Research Ethics
The high price of drugs is receiving due consideration from ethicists, policymakers, and legislators. However, much of this attention has focused on the difference between the cost of drug development and company profits and the possible laws and regulations that could limit a drug’s price once it reaches market. By contrast, little attention has been paid to the ethical implications of high drug prices for the research subjects whose bodies were essential to the drug’s development. Indeed, the future price of a drug is routinely ignored and treated as unknowable during the ethical evaluation of the clinical trials that support its development. In this paper, I will argue that ignoring the future price of a drug during the research process is in tension with all three of the major principles of research ethics: it fails to show respect for the research participants, undermines the quality of risk/benefit judgements made by ethical review committees, and makes it impossible to judge future patient access and assess justice.
- 19 December 2019
- Published by Springer Nature in Journal of Bioethical Inquiry
- Vol. 17 (1) , 29-35
Why High Drug Pricing Is A Problem for Research Ethics
The high price of drugs is receiving due consideration from ethicists, policymakers, and legislators. However, much of this attention has focused on the difference between the cost of drug development and company profits and the possible laws and regulations that could limit a drug’s price once it reaches market. By contrast, little attention has been paid to the ethical implications of high drug prices for the research subjects whose bodies were essential to the drug’s development. Indeed, the future price of a drug is routinely ignored and treated as unknowable during the ethical evaluation of the clinical trials that support its development. In this paper, I will argue that ignoring the future price of a drug during the research process is in tension with all three of the major principles of research ethics: it fails to show respect for the research participants, undermines the quality of risk/benefit judgements made by ethical review committees, and makes it impossible to judge future patient access and assess justice.
- Open Access
- 22 October 2019
- Published by Springer Nature in BMC Medicine
- Vol. 17 (1) , 1-2
Adaptive trials, efficiency, and ethics
- 22 October 2019
- Published by Springer Nature in BMC Medicine
- Vol. 17 (1) , 1-2
Open AccessAdaptive trials, efficiency, and ethics
- Open Access
- 2 August 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (8) , e199732
Data Sharing For Research—Encouraging Signs Amid Ethical Tensions
A study by Kim et al reported the results of a survey experiment that examined patient preferences concerning data sharing. In this experiment, patients were ra
- 2 August 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (8) , e199732
Open AccessData Sharing For Research—Encouraging Signs Amid Ethical Tensions
A study by Kim et al reported the results of a survey experiment that examined patient preferences concerning data sharing. In this experiment, patients were ra